title: Sulfate-conjugated methylprednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis.
abstract: Methylprednisolone (MP) is one of the most widely used corticosteroids for the treatment of inflammatory bowel disease (IBD). However, systemic adverse effects of MP limit its availability for the disease. In present study, sulfate-conjugated methylprednisolone (MPS) was evaluated in vivo as a colon-targeted prodrug of MP and its therapeutic properties against 2,4,6-trinitrobenzenesulfonic acid-induced rat colitis were investigated. Upon oral administration, a large fraction of MPS reached the large intestine, where MPS was converted to MP implying that MPS would deliver MP effectively to the large intestine. The fecal recovery of MP (after MPS administration) was much greater than that after MP administration and the urinary recovery of MP (after MPS administration) was much less than that after MP administration, suggesting that MPS should exhibit enhanced therapeutic activity and reduced systemic adverse effects. Consistent with this notion, MPS was more effective than MP in ameliorating rat colitis. Moreover, the adverse effects of MPS on adrenal function and thymus were much lower than those of MP. Taken together, MPS may be therapeutically superior to MP in IBD treatment.
authors.affiliation: Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
authors.forename: Hyesik
authors.initials: H
authors.lastname: Kong
authors.forename: Younghyun
authors.initials: Y
authors.lastname: Lee
authors.forename: Sungchae
authors.initials: S
authors.lastname: Hong
authors.forename: Jeongoh
authors.initials: J
authors.lastname: Han
authors.forename: Biom
authors.initials: B
authors.lastname: Choi
authors.forename: Yunjin
authors.initials: Y
authors.lastname: Jung
authors.forename: Young Mi
authors.initials: YM
authors.lastname: Kim
mesh_terms: D000284:Administration, Oral; D000311:Adrenal Glands / Q000187:drug effects; D000818:Animals; D003092:Colitis / Q000188:drug therapy*; D003106:Colon / Q000378:metabolism*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D005938:Glucocorticoids / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics*; D008297:Male; D008775:Methylprednisolone / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics*; D011355:Prodrugs; D051381:Rats; D017207:Rats, Sprague-Dawley; D013431:Sulfates / Q000737:chemistry; D013950:Thymus Gland / Q000187:drug effects; D014302:Trinitrobenzenesulfonic Acid
chemical_list: D005938:Glucocorticoids; D011355:Prodrugs; D013431:Sulfates; D014302:Trinitrobenzenesulfonic Acid; D008775:Methylprednisolone